Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Allergic rhinitis

Nose runs – research too

    • Allergology and clinical immunology
    • Education
    • General Internal Medicine
    • RX
  • 4 minute read

Allergic rhinitis (AR) is one of the most common diseases in the world with an incidence of 10% to 40% in the population. Upper respiratory tract disease is manifested by clinical symptoms such as nasal congestion, rhinorrhea, sneezing, and nasal itching. The range of therapeutic options does not seem to be exhausted yet.

Pharmacotherapy of allergic rhinitis includes nasal as well as oral glucocorticoids, antihistamines, leukotriene receptor antagonists, mast cell membrane stabilizers, decongestants, and anticholinergics. Chinese researchers led by Dr. Yifan Meng from the Department of Otolaryngology Head and Neck Surgery, TongRen Hospital, Beijing, took a look at the latest advances and developments in the treatment of AR in their review paper (Table 1) [1]. Progress has been made in a guinea pig allergic asthma model, among others, where inhalation of the arginase inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) was shown to reduce airway hypersensitivity and protect against allergen-induced early and late asthmatic reactions and airway inflammation.

 

 

Although no human studies have been conducted, these results suggest that ABH could be used in the future to treat asthma and allergic rhinitis, the authors write. Because L-arginine is a common substrate for both arginase and NO synthase activity, it has been suggested that inhibition of arginase leads to increased metabolism of L-arginine via NO synthase, which may result in an increase in NO synthesis. This is also known to induce bronchodilation as well as inhibit airway inflammation. Similarly, MP29-02, a combined nasal spray of azelastine hydrochloride and fluticasone propionate, was shown to reduce inflammatory mediators and nasal hyperreactivity in AR.

SLIT vs. SCIT

Allergen-specific immunotherapy (AIT) is the only treatment that targets the underlying pathophysiology. Their efficacy has been documented in several randomized controlled trials, meta-analyses, and systemic reviews. However, the prolonged medication time may be a disadvantage of AIT.

Similar to adult patients AIT is also effective in pediatric patients, and there is evidence that AIT prevents progression of AR to asthma. Overall, however, researchers see benefits with AIT thanks to significant reductions in the use of AR and asthma medications and a reduced risk of asthma.

To date, crude allergen extracts, purified or recombinant allergens, and modified allergens such as allergoids, purified peptides, and novel adjuvants have been used in AIT. In this regard, recombinant B-cell epitope-based grass pollen vaccine BM32 and Lolium perenne peptide (LPP) have been shown to be very effective, safe and well tolerated in the treatment of allergic rhinitis. However, Dr. Meng et al. caution. regarding LPP, that the risk-benefit ratio of subcutaneous LPP immunotherapy (SCIT) has yet to be fully evaluated in a large number of AR patients. However, available data indicated that short-term SCIT with LPP may result in better compliance, as well as fewer systemic reactions and skin reactions in the late phase due to less cross-linking with high-affinity IgE receptors compared to standard SCIT using conventional allergen extracts.

Various approaches to allergen administration in AIT have been tested, including traditional approaches to SCIT and sublingual immunotherapy (SLIT), as well as novel approaches such as intradermal, epicutaneous, intralymphatic, or intranasal applications. With intra-lymphatic immunotherapy, it seems possible to complete the entire treatment within 2 months, whereas SLIT and SCIT usually require treatment periods of about 3 years.

While it has been shown that persistence and adherence to AIT medications are similar for SLIT and SCIT, SLIT is met with willingness to initiate therapy in more patients due to the lower risks of anaphylaxis and serious adverse events, as well as the ease of administration. Although patients on SLIT are more likely to discontinue in the first year than SCIT patients (possibly due to adverse oral effects), the number of individuals who continue treatment into the third year is greater under SLIT.

Hope for cat allergy sufferers

Currently, there are several type 2 targeting biologics such as omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab, of which omalizumab and dupilumab are the most recently launched. A phase 2b study has shown that dupilumab 300 mg every 2 weeks as adjunctive therapy to moderate- to high-dose inhaled corticosteroids (ICS) + long-acting β2-agonists (LABA) can relieve nasal symptoms in patients with uncontrolled persistent asthma and comorbid perennial allergic rhinitis (PAR). In another work, the addition of dupilumab to INCS also reduced disease severity and improved quality of life in adults with chronic rhinosinusitis with nasal polyps (CRSwNP).

Studies on the effects of omalizumab have shown that although intranasal administration of omalizumab did not increase allergen-specific or total IgE levels, subcutaneous administration caused a significant increase in total IgE and IgE-malizumab complex.

Furthermore, Fel d 1, a major feline allergen that triggers asthma and rhinitis, was shown to be neutralized by the addition of anti-Fel d 1 IgY to cat food, reducing active Fel d 1 in cat saliva and degrading hair and dander. The result is a reduction of symptoms in cat-sensitized individuals. Adding anti-Fel d 1 IgY to cat food can reduce Fel d 1 production, allowing AR patients not only to keep cats but also to control the frequency and severity of symptoms without medication, the authors conclude.

 

Literature:

  1. Meng Y, et al: Advances and novel developments in allergic rhinitis. Allergy 2020; 75: 3069-3076; doi: 10.1111/all.14586.

 

InFo PNEUMOLOGY & ALLERGOLOGY 2021; 3(2): 30-31.

Autoren
  • Jens Dehn
Publikation
  • InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
  • Allergic rhinitis
Previous Article
  • Shoulder pain

(Not) a book with seven seals?!

  • Education
  • General Internal Medicine
  • Orthopedics
  • Physical medicine and rehabilitation
  • Rheumatology
  • RX
View Post
Next Article
  • Treatment of relatives

Family members and close relatives as patients

  • CME continuing education
  • Education
  • General Internal Medicine
  • Prevention and health care
  • Psychiatry and psychotherapy
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 10 min
  • Cutaneous lupus erythematosus

From diagnostic workup to successful treatment

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
View Post
  • 4 min
  • Guideline update

Dietary recommendations for Crohn’s disease and colitis

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.